Around 43,500 people in six countries have taken part in the phase three trial run by the pharmaceutical giant and its partner BioNTech.
Volunteers of Pfizer's coronavirus vaccine have reported 'severe' hangover after receiving the first shot of the vaccine and said it left them with headaches, fever and muscle aches. This news comes days after Pfizer's claim that the COVID-19 vaccine is more than 90 per cent effective based on initial trial results.
However a few volunteers have said that they suffered side effects comparable to a flu jab, with one comparing them to 'a severe hangover'.
Around 43,500 people in six countries have taken part in the phase three trial run by the pharmaceutical giant and its partner BioNTech.
One of the volunteers of the trial, Texas lobbyist Glenn Deshields compared side effects of the shot as being similar to 'a severe hangover'. But, he said, the symptoms quickly cleared up.
Another volunteer, identified as Carrie, said she received her first shot of the Pfizer coronavirus vaccine way back in September and another in October.
Carrie said she experienced a 'headache, fever and aches all over her body'. After the second shot, these became 'more severe', she was quoted as saying.
Another volunteer, Deshields said he suffered side effects similar to a 'severe hangover'.
Pfizer and German partner BioNTech said they had found no serious safety concerns yet and expected to seek US emergency use authorization this month, raising the chance of a regulatory decision as soon as December.
If granted, the companies estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.
The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks and produced at scale more rapidly than conventional vaccines. The technology is designed to trigger an immune response without using pathogens, such as actual virus particles.
On the other hand, Israel will sign a provisional deal with Pfizer Inc PFE.N on Friday to receive 8 million doses of the drugmaker's still-experimental coronavirus vaccine from January, the Israeli health minister said.
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
 "Pfizer vaccine volunteers complain of severe hangover, headache, pain")
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
)
){kind=small}
){kind=small}
)
)
)
)
)
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}